Exicure, Inc. (NasdaqCM: XCUR)
Health Care · Biotechnology · US
$1.12
+6.67% today · -76.3% 1Y
Exicure, Inc. (NasdaqCM: XCUR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $7.33M and employs 1 people.
Over the last twelve months the share price has lost 76.3%, trading between 0.94 and 9.48.
Tweenvest scores Exicure, Inc. across four factors: quality 35/100, value 39/100. Its strongest factor is value.
XCUR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $7.33M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.30
- Dividend yield
- —
- Beta (5Y)
- 3.64
- 52-week high
- $9.48
- 52-week low
- $0.94
- Avg volume (3M)
- —
- Shares outstanding
- 6.55M
- Employees
- 1
- Next earnings
- —
About Exicure, Inc.
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
- ISIN
- US30205M3097
- Founded
- 2011
- Listed since
- May 22, 2018
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Immuron LimitedASX: IMC | $7.64M | AU$0.03 | -24.44% |
| Oncotelic Therapeutics, Inc.OTCPK: OTLC | $7.59M | $0.02 | -20.19% |
| Ascelia Pharma AB (publ)OM: ACE | $7.58M | Skr0.56 | -34.65% |
| Aprea Therapeutics, Inc.NasdaqCM: APRE | $7.36M | $0.58 | -3.34% |
| Oncodesign Precision Medicine Société anonymeENXTPA: ALOPM | $7.30M | €0.34 | +3.33% |
| Prostatype Genomics AB (publ)OM: PROGEN | $7.26M | Skr0.10 | +13.29% |
| Zeo ScientifiX, Inc.OTCPK: ZEOX | $7.14M | $0.91 | -23.11% |
| Senti Biosciences Holdings, Inc.NasdaqCM: SNTI | $7.00M | $0.22 | -28.47% |
Figures last refreshed Oct 18, 2026.